AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04576312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo formulation contains the vehicle. The solution is administered in the same way as the active drug. Placebo was only administered for cohorts 1-5.
Trial: NCT01146925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Trial: NCT01850849
Drug: LEO 39652 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01457846
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
Trial: NCT02853500
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
Trial: NCT03100149
Drug: RO7046015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
Trial: NCT03100149
Drug: RO7046015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
Trial: NCT03100149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7046015 placebo will be administered to all participants in the indicated arm.
Trial: NCT01993979
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03133767
Drug: Normal Saline 0.9% Infusion Solution Bag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 liters of intravenous normal saline solution will be administered by peripheral IV
Trial: NCT00553995
Drug: salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate 3-4 grams per day as tolerated for nine days
Trial: NCT00553995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01543321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo consists in:~* 5-week titration to a maximum dose of 200 mg / day~* 5 weeks at stable dose~* 2 weeks in wash-out~The treatment will be blinded for patients and investigators
Trial: NCT02380131
Drug: Oxaliplatin plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
Trial: NCT01349348
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 7.5/15mg , Qd, 7days.
Trial: NCT02344810
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02344810
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01768013
Drug: LEO 90105
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily for four weeks
Trial: NCT02711553
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02711553
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01337401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg, once daily, oral until 24 weeks or disease progression if sooner
Trial: NCT01364987
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02094599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo provided in capsules or as an oral solution in syringes.
Trial: NCT00853983
Drug: [14C] AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, Oral, once
Trial: NCT01629849
Drug: Placebo to BI 1021958 qd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01629849
Drug: Placebo to BI 1021958 bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00836940
Drug: GRC 8200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Trial: NCT03767569
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid daily
Trial: NCT00003789
Drug: isolated limb perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo isolated limb perfusion
Trial: NCT01363843
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX6
Trial: NCT02520479
Drug: P-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
Trial: NCT02520479
Drug: P-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consolidation cycles of P-CHOP are given after radiotherapy
Trial: NCT01525758
Drug: SI000413
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
Trial: NCT03649009
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
Trial: NCT03649009
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
Trial: NCT01656239
Drug: Placebo ( sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999829
Drug: citrate of caffeine
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01999829
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04152759
Drug: Drug: BAT2506 injection Other Names: Simponi(EU-licensed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)
Trial: NCT03153852
Drug: Modified Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Jessner's solution will be applied on the right side until frosting
Trial: NCT03153852
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
Trial: NCT00450216
Drug: Ibuprofen/famotidine
RxNorm normalized name: ibuprofen/famotidine 800 mg-26.6 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
Trial: NCT00450216
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 800mg administered orally 3 times daily for 24 weeks
Trial: NCT03119766
Drug: Kolofort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03119766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04193774
Drug: Oxybuprocaine Hydrochloride 0.4% Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of topical anesthesia in one eye
Trial: NCT00774982
Drug: Delayed Release 6 mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
Trial: NCT00774982
Drug: 6 Mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
Trial: NCT02575703
Drug: [¹⁴C]-LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3023414 in solution containing approximately 100 microCi \[¹⁴C\]-LY3023414
Trial: NCT03534648
Drug: PF-06865571 administered Day 1-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06865571 administered Q12hr on Day 7-14
Trial: NCT03534648
Drug: PF-05221304 administered Day 1-14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05221304 administered Q12hr on Days 1-14
Trial: NCT00193505
Drug: 90Y Zevalin
RxNorm normalized name: Zevalin KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04052737
Drug: PMZ-1620 (sovateltide) along with standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
Trial: NCT01607892
Drug: KPT-330
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00036790
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03792009
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Trial: NCT01877655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT04083495
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 administered IV for 3 days for lymphodepletion 2-14 days prior to second cell infusion and 2-14 days prior to the first cell infusion for subjects who have previously had hypersensitivity to bendamustine
Trial: NCT01901328
Drug: CB-5945
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03047330
Drug: Estradiol withdrawal
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
Trial: NCT02258412
Drug: hand antiseptic with CHG and alcohol
RxNorm normalized name: CHG Teat Dip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
Trial: NCT02258412
Drug: Alcohol hand sanitizer foam
RxNorm normalized name: BENZETHONIUM CHLORIDE 2.5 g in 1 L TOPICAL LIQUID [Sierra Soft Non-Alcohol Hand Sanitizer Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
Trial: NCT01689038
Drug: F17464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00295945
Drug: fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02283814
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00671281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
Trial: NCT05751525
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenlclamide / glyburide
Trial: NCT04285528
Drug: General anesthetia Fentanyl and Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
Trial: NCT01149200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo as enteric-coated oral hard gelatin capsule, administered twice daily
Trial: NCT00520026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01412879
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01412879
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01412879
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT01412879
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03184870
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04029376
Drug: Iberogast®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
Trial: NCT02993237
Drug: DRV/COBI FDC placebo tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
Trial: NCT02993237
Drug: D/C/F/TAF FDC placebo tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
Trial: NCT01538771
Drug: Control Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
Trial: NCT03368859
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT03368859
Drug: Fluorouracil - bolus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT03368859
Drug: Fluorouracil - infusion
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT03368859
Drug: ABT-165
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT00796718
Drug: Capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
Trial: NCT02354833
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02266550
Drug: [14C] BILL 284 BS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345605
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
Trial: NCT02210780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive substance containing no medicine administered via subcutaneous injection.
Trial: NCT00003956
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003956
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06218901
Drug: immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06218901
Drug: Targeted Therapy Agent
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004255
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02966314
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
Trial: NCT03784378
Drug: RXDX-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
Trial: NCT01179295
Drug: BAY86-9766
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY86-9766 30 mg twice a day (bid).
Trial: NCT01179295
Drug: BAY86-9766
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY86-9766 50 mg twice a day (bid).
Trial: NCT01179295
Drug: BAY86-9766
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY86-9766 100 mg once a day (od)
Trial: NCT01179295
Drug: BAY86-9766
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY86-9766 60 mg once a day (od)
Trial: NCT04122196
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
Trial: NCT01929083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive oral placebo two capsules once daily every evening for 7 days
Trial: NCT01075087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral TAP block using sterile normal saline.
Trial: NCT02331576
Drug: rocaine
RxNorm normalized name: Procaine
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02331576
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01829048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q12h
Trial: NCT01937312
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo comparator
Trial: NCT01937312
Drug: Prostaglandin analogue
RxNorm normalized name: Prostaglandin analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03723447
Drug: Bupivacaine/epinephrine/dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
Trial: NCT02656888
Drug: Irlanda-1-Association
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Trial: NCT02656888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Trial: NCT01175512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Trial: NCT01608334
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
Trial: NCT01608334
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
Trial: NCT04401059
Drug: First or third generation EGFR-TKIs
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: refer to the drug label.
Trial: NCT00326820
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no